Open Access Open Access  Restricted Access Subscription or Fee Access

Monoclonal Antibodies used for Therapeutics Purpose, its Application

Supriya Sharma

Abstract


The growing demand of monoclonal antibodies (mAbs) for diagnostic and therapeutic purposes has led to the creation of large-scale manufacturing techniques, with productivity gains attained through constant optimization of the underlying systems. In recent years, the frequency of monoclonal antibodies (mAbs) which have been authorized for therapeutic purposes and clinical studies has expanded dramatically. Numerous enhancements and changes to monoclonal antibodies have just been created in response to the adverse effects and restrictions of mAbs. These changes have made it easier to use mAbs in a variety of therapeutic purposes, including the treatment of many viral diseases disorders caused by the bacteria, viruses, fungi, and parasites. Monoclonal antibodies are most often used to treat non-infectious diseases including malignancy, immunological diseases, osteoarthritis, as well as other organ transplant-related ailments.


Full Text:

PDF

References


Treviño SR, Permenter AR, England MJ, Parthasarathy N, Gibbs PH, Waag DM, Chanh TC, Trevin SR. Monoclonal Antibodies Passively Protect BALB/c Mice against Burkholderia mallei Aerosol Challenge. Infect Immun 2006; 74 (3): 1956–1961.

Smith BT. Introduction to Diagnostic and Therapeutic. Univ New Mex Heal Sci Cent 2012; 17(0039): 1–34.

Ribatti D. From the discovery of monoclonal antibodies to their therapeutic application: An historical reappraisal, Immunol Letters 2014; 161 (1): 96–99. 4.

Wang S. Advances in the production of human monoclonal antibodies. Antibo Techn Journ 2011; 1: 1-4.

Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discovery 2010; 9 (10): 767–774.

Ghosh S, Ansar W. Monoclonal Antibodies: A Tool in Clinical Research. Indian J Clin Med 2013; 4: 9–12.

Li J, Zhu Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin 2010; 31 (9): 1198–1207.

Reff ME, Hariharan K, Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 2002; 9 (2): 152–66.

Rita Costa A, Elisa Rodrigues M, Henriques M, et al. Guidelines to cell engineering for monoclonal antibody production. European J Pharma and Biopharm 2010; 74 (2): 127–138.

Bernett MJ, Karki S, G Moore GL, et al. Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions. J Mol Biol 2010; 396 (5): 1474–1490.

Posner J, Barrington P, Brier T, et al. Monoclonal Antibodies: Past, Present and Future. Handbook of experimental pharmacology. 2019; 260: 81–141.

Bayer V. An Overview of Monoclonal Antibodies. Seminars in oncology nursing. 2019; 35(5):150927.

Tiller KE, Tessier PM. Advances in Antibody Design. Annual review of biomedical engineering. 2015; 17: 191–216.

Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacology research. 2019; 7(6): e00535.

Shepard HM, Phillips GL, D Thanos C, et al. Developments in therapy with monoclonal antibodies and related proteins. Clinical medicine (London, England). 2017; 7 (3): 220–232.

Buss NA, Henderson SJ, McFarlane M, et al. Monoclonal antibody therapeutics: history and future. Current opinion in pharmacology. 2012; 12 (5): 615–22.

Demlova R, Valík D, Obermannova R, Zdra Žilová-Dubská L. The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors. Physiological research. 2016; 65 (Suppl 4): S455–S462.

Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006.

Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology American Society of Hematology. Education Program. 2016 (1): 567–572.

Vergara-Jimenez J, Tricoci P, Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention. Vascular health and risk management. 2010; 6: 39–45.

Krishnamurthy A, Jimeno A, Bispecific antibodies for cancer therapy: A review. Pharmacology. 2018; 185: 122–134.




DOI: https://doi.org/10.37628/ijmb.v8i1.758

Refbacks

  • There are currently no refbacks.